Abstract CT098: A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced IDH-mutant cholangiocarcinoma and other solid tumors

异柠檬酸脱氢酶 恶心 IDH1 医学 不利影响 呕吐 内科学 胶质瘤 胃肠病学 药理学 肿瘤科 癌症研究 突变体 生物 生物化学 基因 酶
作者
Jordi Ahnert Rodon,Lipika Goyal,Teresa Mercade Macarulla,Masafumi Ikeda,Shunsuke Kondo,Do‐Youn Oh,Li‐Yuan Bai,Makoto Ueno,Antoîne Italiano,Kyriakos P. Papadopoulos,David Robert Spigel,Sani Haider Kizilbash,Rasha Cosman,Joon Oh Park,Li‐Tzong Chen,Tomoya Yokota,Anita Ahmed Turk,Chih‐Yi Liao,Rachna T. Shroff,Anthony B. El-Khoueiry
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:83 (8_Supplement): CT098-CT098 被引量:17
标识
DOI:10.1158/1538-7445.am2023-ct098
摘要

Abstract Background: Isocitrate dehydrogenase 1/2 (IDH1/2) is mutated in a subset of cholangiocarcinoma (CCA), gliomas, and other solid tumors. LY3410738 is a potent, selective, covalent, dual inhibitor of IDH1/2 mutations (IDH1/2m). LY3410738 binds covalently at a novel binding site, enabling continued potency in preclinical models in the setting of second site IDH resistance mutations. We present initial results from the first-in-human phase 1 study of oral LY3410738 in patients (pts) with IDH1/2m CCA, and IDH1m glioma or other solid tumors. Methods: Dose escalation (3+3 design) evaluated LY3410738 monotherapy in advanced IDHm CCA and other solid tumors (NCT04521686). Key objectives included determining the RP2D, safety, PK, PD (inhibition of plasma D-2-HG), and preliminary antitumor activity. Results: As of 28 July 2022, 80 pts including 42 with CCA (33 IDH1m, 9 IDH2m), 27 with glioma (IDH1m), and 11 other tumor types (IDH1m) received LY3410738 dosed at 25-600 mg QD or 300 mg BID. Pts were median 52 years of age (range, 23-80) with a median of 2 prior therapies (range, 1-7). 19% of CCA pts had received prior IDH1 inhibitor. Median time on treatment was 3.7 months (range, 0.1-19). No DLTs or treatment related deaths were observed; the MTD was not reached. Treatment emergent adverse events (TEAEs) ≥15% included nausea (35%), vomiting (21%), and decreased appetite (19%) and were mostly grade 1-2. Most frequent grade ≥3 TEAEs >2% were anemia (4%), cholangitis (3%), headache (3%), decreased lymphocyte count (3%), and hyponatremia (3%). LY3410738 exposure was dose proportional. In pts with IDH1m cancers, LY3410738 achieved sustained D-2-HG inhibition at all dose levels, including in pts who received prior IDH1 inhibitor. In pts with IDH2m cancers, a higher dose (≥150 mg daily dose) was required for D-2-HG inhibition. Among the 42 pts with R/R CCA, the best response included 1 PR and 22 SD. Of the 22 glioma pts with contrast enhancing tumors, best response included 3 PR and 9 SD. Conclusions: LY3410738 demonstrated a favorable safety profile with potent and sustained D-2-HG inhibition in pts with IDH1/2m advanced solid tumors. Consistent with the expectations for IDH inhibitor monotherapy in this setting, CCA and glioma pts exhibited prolonged stable disease. RP2D evaluation is ongoing. Updated data on LY3410738 monotherapy will be presented at the meeting. Citation Format: Jordi Rodon, Lipika Goyal, Teresa Macarulla Mercade, Masafumi Ikeda, Shunsuke Kondo, Do-Youn Oh, Li-Yuan Bai, Makoto Ueno, Antoine Italiano, Kyriakos Papadopoulos, David Spigel, Sani H. Kizilbash, Rasha Cosman, Joon Oh Park, Li-Tzong Chen, Tomoya Yokota, Anita A. Turk, Chih-Yi Liao, Rachna Shroff, Anthony El-Khoueiry, Taroh Satoh, Antoine Hollebecque, Mitesh J. Borad, Nilofer Azad, Kurt A. Jaeckle, Herbert H. Loong, Jorge Adeva, Wei Peng Yong, Junjie Zhao, Hui Liu, Anna M. Szpurka, Ivelina Gueorguieva, Kamnesh R. Pradhan, Xiaojian Xu, James J. Harding. A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced IDH-mutant cholangiocarcinoma and other solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT098.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ZSW完成签到,获得积分10
刚刚
爱而不得发布了新的文献求助10
1秒前
杜du完成签到,获得积分20
2秒前
2秒前
今后的应助被玉米侠采纳,获得10
6秒前
razor发布了新的文献求助30
7秒前
8秒前
zyl666完成签到,获得积分10
9秒前
zlx完成签到,获得积分10
9秒前
风吹麦浪的应助被整齐冬菱采纳,获得10
11秒前
顾矜的应助被alvin采纳,获得10
12秒前
田様的应助被帅气的惜天采纳,获得10
12秒前
12秒前
852的应助被熊98采纳,获得10
13秒前
15秒前
yiying完成签到 ,获得积分10
17秒前
搜集达人的应助被DXL采纳,获得10
17秒前
18秒前
紫垣完成签到,获得积分10
18秒前
19秒前
19秒前
披萨好吃酱完成签到,获得积分10
19秒前
chestnut灬完成签到,获得积分10
19秒前
alvin对应助文件撤销了驳回
19秒前
20秒前
20秒前
李希完成签到,获得积分10
20秒前
zzz1完成签到,获得积分10
20秒前
单纯英姑发布了新的文献求助10
20秒前
Fllipped完成签到 ,获得积分10
21秒前
21秒前
可爱的函函的应助被洁净雅彤采纳,获得10
22秒前
拉长的南松完成签到 ,获得积分10
23秒前
熊98发布了新的文献求助10
24秒前
libra完成签到 ,获得积分10
24秒前
CodeCraft的应助被夙夙采纳,获得10
24秒前
玉米侠发布了新的文献求助10
24秒前
yifei完成签到,获得积分10
26秒前
爆米花的应助被予安采纳,获得30
26秒前
wanci的应助被迟安歌采纳,获得10
27秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188563
求助须知:如何正确求助?哪些是违规求助? 9576328
关于积分的说明 21846521
捐赠科研通 7786563
什么是DOI,文献DOI怎么找? 3435354
关于科研通互助平台的介绍 2559627
邀请新用户注册赠送积分活动 2482336